Identifying treatments that halt progression of pulmonary disease in cystic fibrosis

Pediatric Research

Volumn 41, Issue 2, 1997, Pages 161-165

  Davis, Pamela B ^a,b   Byard, Pamela J ^a   Konstan, Michael W ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IBUPROFEN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DISEASE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0031021662     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/00006450-199702000-00001     Document Type: Article

References (23)

1. Davis PB 1994 Evolution of therapy for cystic fibrosis. N Engl J Med 331:672-673
2. Fitzsimmons SC 1993 The changing epidemiology of cystic fibrosis. J Pediatr 122:1-9
3. Ramsey BW, Boat TF 1994 Outcome measures for clinical trials in cystic fibrosis. J Pediatr 124:177-192
4. Kerem E, Reisman J, Corey M, Canny GJ, Levison H 1992 Prediction of mortality in patients with cystic fibrosis. N Engl J Med 326:1187-1191
5. Wagener JS, Taussig LM, Burrows B, Hernried L. Boat T 1980 Comparison of lung function and survival patterns between cystic fibrosis and emphysema or chronic bronchitis patients. In: Sturgess JM (ed) Perspectives in Cystic Fibrosis: Proceedings of the Eighth International Cystic Fibrosis Congress, Toronto, May 26-30, 1980. Canadian Cystic Fibrosis Foundation, Toronto, pp 236-245
6. Cooper PJ, Robertson CF, Hudson IL, Phelan PD 1990 Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol 8:16-22
7. Nickerson BG, Lernen RJ, Gerdes CB, Wegmann MJ, Robertson G 1980 Within-subject variability and per cent change for significance of spirometry in normal subjects and in patients with cystic fibrosis. Am Rev Respir Dis 122:859-866
8. Corey M, Levison H, Crozier D 1976 Five to seven-year course in pulmonary function in cystic fibrosis. Am Rev Respir Dis 114:1085-1092
9. Konstan MW, Byard PJ, Hoppel CL. Davis PB 1995 Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332:848-854
10. Standardization of spirometry - 1987 update: statement of the American Thoracic Society 1987 Am Rev Respir Dis 136:1258-1298
11. Knudson RJ, Lebowitz MD, Holbert CL, Burrows B 1983 Changes in the normal maximal expiratory flow-volume curve with growth and aging Am Rev Respir Dis 127:725-734
12. Knowles MR, Hohneker KW, Zhou ZQ, Olsen JC, Noah TL, Hu PC, Leigh MW, Engelhardt JF, Edwards LJ, Jones KR, Grossman M, Wilson JM, Johnson LG, Boucher RC 1995 A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 333:823-831
13. Crystal RG, McElvaney NG, Rosenfeld MA, Chu C-S, Mastrangeli A, Hay JG, Brody SL. Jaffe HA, Eissa NT, Danel C 1994. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 8:42-51
14. Hay JG, McElvaney NG, Herena J, Crystal R 1995 Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector. Hum Gene Ther 6:1487-1496
15. Knowles MR, Clarke LL, Boucher RC 1991. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 325:533-538
16. Eidelman O, Guay Broder C, van Galen PJ, Jacobson KA, Fox C, Turner RJ, Cabantchik ZI, Pollard HB 1992. A1 adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc Natl Acad Sci USA 89:5562-5566
17. Gribkoff VK, Champigny G, Barbry P, Dworetzky SI, Meanwell NA, Lazdunski M 1994 The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J Biol Chem 269:10983-10986
18. Kelley TJ, Al-Nakkash L, Drumm ML 1995 CFTR-medialed chloride permeability is regulated by type III phosphodiesterases in airway epithelial cells. Am J Respir Cell Mol Biol 13:657-664
19. Ellis DA, Thornley PE, Wightman AJ, Walker M, Chalmers J, Crofton JW 1981 Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis. Thorax 36:659-664
20. Kerem E, Corey M, Gold R, Levison H 1990 Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 116:714-719
21. Dankert-Roelse JE, te Meerman GJ 1995 Long term prognosis of patients with cystic fibrosis in relation to early detection by neonatal screening and treatment in a cystic fibrosis centre. Thorax 50:712-718
22. Gan K-H, Veeze HJ, Van den Ouweland AMW, Halley DJJ, Scheffer H, VanderHout A, Overbeek SE, DeJongste JC, Bakker W, Heijerman HGM 1995 A cystic fibrosis mutation associated with mild lung disease. N Engl J Med 333:95-99
23. Kovesi T, Corey M, Levison H 1993 Passive smoking and lung function in cystic fibrosis. Am Rev Respir Dis 148:1266-1271